1. Clinical & Scientific Overview
Glycopyrronium & Indacaterol (Ultra-LABA / LAMA COPD Bronchodilators) (TIP-MED-000177, Reference Code [9.13]) is classified under
Respiratory, Asthma, COPD & Allergy Medicines (Ch 09) as a Long-Acting Muscarinic Antagonist (LAMA) & Ultra-Long-Acting Beta-2 Agonist (LABA) for COPD (Schedule H).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 09 [9.13], p. 120): Glycopyrronium (LAMA): Airz (Glenmark), Seebri Breezhaler (Novartis), Glycohale (Cipla). Indacaterol + Glycopyrronium (LABA + LAMA): Ultibro Breezhaler (Novartis), Airz-FB (+ Budesonide Triple) — Strengths & Dosage Forms: Glycopyrronium Inhalation Capsules (DPI): 50 mcg Once Daily; Nebuliser Respule: 25 mcg/mL. Indacaterol 110 mcg + Glycopyrronium 50 mcg DPI Capsule: Once Daily
Glycopyrronium Inhalation Capsules (DPI): 50 mcg Once Daily; Nebuliser Respule: 25 mcg/mL. Indacaterol 110 mcg + Glycopyrronium 50 mcg DPI Capsule: Once Daily
3. Mechanism of Action & Pharmacodynamics
Long-Acting Muscarinic Antagonist (LAMA) & Ultra-Long-Acting Beta-2 Agonist (LABA) for COPD (Schedule H) acting on target receptor/enzyme pathways in Respiratory, Asthma, COPD & Allergy Medicines (Ch 09): clinical efficacy is mediated via Long-Acting Muscarinic Antagonist (LAMA) & Ultra-Long-Acting Beta-2 Agonist (LABA) for COPD (Schedule H) for Maintenance bronchodilator therapy for GOLD Group A/B/E Chronic Obstructive Pulmonary Disease (COPD) — Dual LABA+LAMA (Indacaterol + Glycopyrronium) is GOLD 2024–2026 first-line maintenance therapy for symptomatic COPD!.
4. Therapeutic Indications & Evidence-Supported Uses
- Maintenance bronchodilator therapy for GOLD Group A/B/E Chronic Obstructive Pulmonary Disease (COPD) — Dual LABA+LAMA (Indacaterol + Glycopyrronium) is GOLD 2024–2026 first-line maintenance therapy for symptomatic COPD!
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: 1 capsule (Glycopyrronium 50 mcg or Indacaterol 110 mcg + Glycopyrronium 50 mcg) inhaled ONCE DAILY at the same time each morning via the dedicated Dry-Powder Inhaler
Administration & Meal Timing: CRITICAL ROUTE WARNING: DPI capsules are for ORAL INHALATION ONLY via the inhaler device — NEVER SWALLOW the capsule with water! | Morning (Once Daily at the same hour)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Glycopyrronium is significantly renally excreted — in severe CKD (eGFR <30 mL/min), monitor for urinary retention/dry mouth. Hepatic: No adjustment needed
Renal: Glycopyrronium is significantly renally excreted — in severe CKD (eGFR <30 mL/min), monitor for urinary retention/dry mouth. Hepatic: No adjustment needed
Renal: Glycopyrronium is significantly renally excreted — in severe CKD (eGFR <30 mL/min), monitor for urinary retention/dry mouth. Hepatic: No adjustment needed
7. Contraindications, Precautions & High-Risk Warnings
- Indacaterol (LABA without ICS) is CONTRAINDICATED in Asthma! Glycopyrronium (LAMA) requires caution in narrow-angle glaucoma, symptomatic prostatic hyperplasia (BPH) / bladder-neck obstruction, and severe CKD. Never use for acute rescue
Key Clinical Precautions: Renal: Glycopyrronium is significantly renally excreted — in severe CKD (eGFR <30 mL/min), monitor for urinary retention/dry mouth. Hepatic: No adjustment needed
8. Adverse Effects Profile
- Dry mouth (antimuscarinic effect), nasopharyngitis, transient 'indacaterol cough' (brief self-limiting cough within 15s of inhaling powder in ~15% — reassure patient!), mild tremor/tachycardia
- Acute urinary retention in men with BPH, acute angle-closure glaucoma (if powder enters eyes), paradoxical bronchospasm, tachyarrhythmias/hypokalaemia
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- DO NOT combine with another LAMA (Tiotropium, Umeclidinium) or another SAMA (Ipratropium) — duplicate antimuscarinic toxicity! Do not combine with another LABA (Formoterol, Salmeterol); Non-selective Beta-Blockers antagonise Indacaterol
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: THREE COUNTER RULES: (1) Pierce and inhale the capsule through the Breezhaler/Rotahaler device — NEVER swallow the capsule; (2) Stop using Tiotropium (Tiova) or Ipratropium (Duolin) when starting Glycopyrronium/Ultibro to avoid double anticholinergic urinary block; (3) Older men with prostate enlargement should report any difficulty passing urine
- Meal & Clock Timing Instruction: CRITICAL ROUTE WARNING: DPI capsules are for ORAL INHALATION ONLY via the inhaler device — NEVER SWALLOW the capsule with water! (Morning (Once Daily at the same hour))
- Missed Dose Protocol: Inhale on the same day if remembered; skip if next day; never inhale 2 capsules in one day
- Geriatric Dispensing Pearl: Check BPH urinary symptoms and verify adequate peak inspiratory flow (>30–60 L/min) to use a dry-powder inhaler in frail older COPD patients
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Glycopyrronium Inhalation Capsules (DPI): 50 mcg Once Daily; Nebuliser Respule: 25 mcg/mL. Indacaterol 110 mcg + Glycopyrronium 50 mcg DPI Capsule: Once Daily
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 09 [9.13] (p. 120)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [9.3]-C82 Budesonide (MART/AIR FDC) / Fluticasone — Fast-Onset Long-Acting Beta-2 Adrenergic Agonist (LABA; 12-Hour B
- [9.4]-C83 Fluticasone Propionate (ICS — Slow-Onset Long-Acting Beta-2 Adrenergic Agonist (LABA; 12-Hour B
- [9.4]-C84 LABA FDC) — Slow-Onset Long-Acting Beta-2 Adrenergic Agonist (LABA; 12-Hour B
- [9.6]-C85 Ipratropium + Levosalbutamol / Salbutamol [FDC] — Short-Acting Muscarinic Antagonist (SAMA; 6-to-8 Hour Anticholine
